Nykode Therapeutics AS (OSL:NYKD)
kr 2.974 -0.046 (-1.52%) Market Cap: 971.15 Mil Enterprise Value: -397.26 Mil PE Ratio: 0 PB Ratio: 0.65 GF Score: 46/100

Q1 2023 Nykode Therapeutics ASA Earnings Call Transcript

May 12, 2023 / 08:01AM GMT
Release Date Price: kr26.78 (+5.68%)
Operator

Hello, and welcome to the Nykode Therapeutics first quarter 2023 earnings conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to your host, CEO, Michael Engsig. Michael, please go ahead.

Michael Engsig
Nykode Therapeutics ASA - CEO

Thank you very much, Kevin, and a very warm welcome to everybody on the call this morning in Norway and Scandinavia. We're going to run this one here for our entire audience, including also the international. So we're going to run it in English this morning here.

So just a quick look at our forward-looking statements. And as usual, we assume that you are familiar with these statements, so we'll quickly move on. Again, as usual, I had to tour you. I'm joined here today by Agnete Fredriksen, our Chief Business Officer and Co-Founder; as well as Harald Gurvin, our Chief Financial Officer. I will take you through both a highlight level of the data that we presented in this quarter here, as well as, of course, a deep dive into

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot